Insider filing · RNAC

Timothy A Springer bought $4.2M of Cartesian Therapeutics (RNAC)

Executed Oct 3 2024, disclosed Oct 4 2024, 1 day later.

Over the 21 trading sessions from the disclosed entry session (Oct 4 2024), the stock returned -17.5% (delay-adjusted); from the execution session (Oct 3 2024), +10.6%. Derived: entry at the session's open, exit at the close 20 sessions later.

TS Timothy A Springer Director profile →

Timothy A Springer (Director) filed 11 Form 4 reports in the past 24 months (11 purchases, 0 sales), most often in RNAC. Across 11 priced purchase filings, the average 21-session return was +8.0% from execution and +3.1% from disclosure (delay-adjusted; derived). The largest single filing was $40.0M of TECX (789,294 sh across 2 lots, as filed), executed Feb 5 2025.

RNAC RNAC RNAC · 14 filings in 24 months ticker → Insider filings, newest first→ View the original filing at www.sec.gov→